Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

Swenson, Christine E.; Bolcsak, Lois E.; Batist, Gerald; Guthrie, Troy H.; Tkaczuk, Katherine H.; Boxenbaum, Harold; Welles, Lauri; Chow, Shein‐Chung; Bhamra, Rupinder; Chaikin, Philip

doi:10.1097/00001813-200303000-00008

Cited by 102 publications

(58 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Doksorubisinin ilaç taşıyıcı sistemlerden birisi olan lipozomlarla birleştirilmesiyle farmakokinetik ve toksik özellikleri değişmektedir. 5 Lipozomal doksorubisin alan hastalarda gelişen mukokütanöz yan etkilerin klinik özelliklerinin değerlendirildiği ça-lışmamızda en sık, "el-ayak sendromu" olarak da bilinen, akral eritrodisestezi izlendi. Akral eritrodisestezi, iki ya da üç kür kemoterapi sonrasında ortaya çıkıp, dört hastada evre III şiddetteki lezyonlarla seyretmekteydi.…”

Section: Discussionunclassified

Mucocutaneous Side Effects Associated with Liposomal Doxorubicin Therapy: Case Series

Ada¹,

Şenel²,

Ayhan³

2011

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

993Lipozomal Doksorubisin Tedavisine Bağlı Mukokütanöz Yan Etkiler: Olgu Serisi Ö ÖZ ZE ET T Li po zo mal dok so ru bi sin, dok so ru bi si nin ye ni bir for mu dur. Dok so ru bi sin den da ha et ki li olup kar di yak ve mi ye lo süp re sif yan et ki ler ise na di ren iz len mek te dir. Bu nun la bir lik te, li po zo mal dok so ru bi si nin sık rast la nan ve do za ba ğım lı ola rak ge li şe bi len çe şit li mu ko kü ta nöz yan et ki le ri bil di ril mek te dir. Bu ça lış ma da li po zo mal dok so ru bi sin te da vi si ne bağ lı or ta ya çı kan mu ko kü ta nöz yan et ki le rin kli nik özel lik le ri nin be lir len me si amaç lan mış tır. Li po zo mal dok so ru bi sin te da vi si alan ve çe şit li mu ko kü ta nöz yan et ki ler ne de niy le Ocak 2008 ile Ni san 2009 ta rih le ri ara sın da Der mato lo ji bö lü mü ne kon sül te edi len ar dı şık sekiz has ta de ğer len di ril di. Mu ko kü ta nöz yan et ki le rin klinik özel lik le ri ve or ta ya çık tı ğı kür sa yı sı kay de dil di. Yan et ki le rin şid de ti, Ulu sal Kan ser Ens ti tü sü' nün tok sik et ki kri ter le ri uyar la na rak I ile IV ara sın da ev re len di. Has ta la rın tü mün de (%100) ak ral erit ro di ses te zi mev cut tu. Ay rı ca, altı (%75) has ta da in ter tri go-ben ze ri erüp si yon, bir (%12.5) has ta da yay gın fol li kü ler erüp si yon ve iki (%25) has ta da sto ma tit sap tan dı. Bir has ta da (%12.5) pal mar böl ge ler de ye ni ge li şen me la no tik ma kül ler iz len di. Ak ral erit ro di ses te zi li dört hasta ile in ter tri go-ben ze ri erüp si yon lu bir has ta da ev re III şid det te lez yon lar gö rül dü. Mu ko kü ta nöz yan et ki ler, üç has ta da üçüncü kür, di ğer has ta lar da ise ikinci kür ke mo te ra pi son ra sın da ge liş ti. Lipo zo mal dok so ru bi sin te da vi si ne öz gü, do za ba ğım lı ola rak ge li şen ve sık lık la ya şam ka li te si ni dü -şü ren mu ko kü ta nöz yan et ki ler gö rü le bil mek te dir. Bu yan et ki le rin kli nik özel lik le ri nin bi lin me si ve ge rek li ön lem le rin alın ma sı önem li dir.A An na ah h t ta ar r K Ke e l li i m me e l le er r: : Pegile lipozomal doksorubisin; ilaç tedavisi; istenmeyen etkiler A AB BS S T TR RA AC CT T Liposomal doxorubicin is a new form of doxorubicin. Compared to free doxorubicin, liposomal form has been associated with increased efficacy, reduced myelosuppression and cardiac side effects. However, mucocutaneous side effects still occur and can be dose-limiting. In this study, we aimed to determine the clinical features of mucocutaneous side effects associated with liposomal doxorubicin therapy. We evaluated eight consecutive patients who were referred to Dermatology Department between January 2008 and April 2009 because of various mucocutaneous side effects attributed to liposomal doxorubicin therapy. The clinical features of side effects and the onset time after chemotherapy cycles were recorded. A severity scale of I through IV was adopted for toxic effects to the skin, based on the common toxicity criteria of National Cancer Instittute. Acral erythrodysesth...

show abstract

Section: Discussionunclassified

Mucocutaneous Side Effects Associated with Liposomal Doxorubicin Therapy: Case Series

Ada¹,

Şenel²,

Ayhan³

2011

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

show abstract

“…After i.v. administration in MBC patients, Myocet may slow blood clearance and reduce the distribution volume of the encapsulated agents in comparison with the aqueous formulation (Swenson et al 2003).…”

Section: Discussionmentioning

confidence: 99%

“…First, it is well known that both prolonging the duration and elevating the concentration of ADR enhances its cytotoxic efficacy (Rupniak et al 1983). Swenson et al (2003) reported that compared with conventional ADR, Myocet substantially slowed the blood clearance and improved the plasma concentrations of total ADR after i.v. administration.…”

Section: Discussionmentioning

confidence: 99%

Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model

Jh¹

2005

Endocrine Related Cancer

View full text Add to dashboard Cite

The antitumor effects of small-sized liposomal Adriamycin (LADR) administered by various routes were investigated in rabbits bearing well-developed VX2 tumors in the mammary gland. Rabbits received s.c. or i.v., or s.c. combined with i.v., injections of LADR 6 weeks after tumor implantation. The i.v. route showed a significant inhibitory effect on breast tumors and distant metastases. In comparison, metastases in axillary and mediastinal lymph nodes were more efficiently inhibited after s.c. injection. LADR administered concurrently by both the i.v. and s.c. routes produced satisfactory therapeutic activities on both primary breast tumors and metastases in local-regional lymph nodes, lungs and liver, as shown by slowed growth rates, decreased mRNA expression of proliferating cell nuclear antigen, and extensive necrosis and apoptosis of tumor cells. It is concluded that smallsized LADR administered s.c. provides reliable efficacy on lymphatic metastases of breast cancer and that the addition of treatment by the s.c. route to that by the conventional i.v. route can be recommended as a promising procedure to enhance chemotherapeutic effects in patients with metastatic breast cancer.

show abstract

“…Myocet Ò was developed to selectively reduce the release of active doxorubicin in normal tissues while increasing its concentration in tumor tissues, with the aim of reducing toxicity and increasing efficacy [12,[14][15][16]. Because of their size, the liposomes do not pass through the capillary beds of normal tissues while they readily diffuse through the chaotic and highly permeable capillaries of tumors.…”

Section: Introductionmentioning

confidence: 99%

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

Barco¹,

Colomer²,

Calvo³

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

Cited by 102 publications

References 16 publications

Mucocutaneous Side Effects Associated with Liposomal Doxorubicin Therapy: Case Series

Mucocutaneous Side Effects Associated with Liposomal Doxorubicin Therapy: Case Series

Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

Contact Info

Product

Resources

About